Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy

被引：0
|
作者：
Dimopoulos, Meletios A. [1 ]
Terpos, Evangelos [1 ]
Gavriatopoulou, Maria [1 ]
Kalapanida, Despoina [1 ]
Eleutherakis-Papaiakovou, Evangelos [1 ]
Roussou, Maria [1 ]
Mparmparoussi, Despoina [2 ]
Zomas, Athanasios [3 ]
Gika, Dimitra [1 ]
Kartasis, Zafiris [4 ]
Matsouka, Charis [2 ]
Kostis, Evangelos [1 ]
Kontogiannis, Sofoklis [1 ]
Konstantopoulos, Kostas [1 ]
Kastritis, Efstathios [1 ]
机构：
[1] Univ Athens, Sch Med, Athens 11528, Greece
[2] Alexandra Gen Hosp, Athens, Greece
[3] St Anargiri Canc Hosp, Athens, Greece
[4] Gen Hosp Chalkida, Chalkida, Greece
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Lenalidomide enhances anti-myeloma cellular immunity
    Luptakova, Katarina
    Rosenblatt, Jacalyn
    Glotzbecker, Brett
    Mills, Heidi
    Stroopinsky, Dina
    Kufe, Turner
    Vasir, Baldev
    Arnason, Jon
    Tzachanis, Dimitri
    Zwicker, Jeffrey I.
    Joyce, Robin M.
    Levine, James D.
    Anderson, Kenneth C.
    Kufe, Donald
    Avigan, David
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (01) : 39 - 49
  • [32] The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma
    E Terpos
    M-A Dimopoulos
    O Sezer
    Leukemia, 2007, 21 : 1875 - 1884
  • [33] The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma
    Terpos, E.
    Dimopoulos, M-A
    Sezer, O.
    LEUKEMIA, 2007, 21 (09) : 1875 - 1884
  • [34] Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents
    M N Saha
    Y Chen
    M-H Chen
    G Chen
    H Chang
    British Journal of Cancer, 2014, 110 : 2224 - 2231
  • [35] Evaluating the contribution of anti-myeloma immunity for the efficacy of oncolytic reovirus therapy.
    Mueller, Louise M. E.
    Parrish, Christopher
    Migneco, Gemma
    Scott, Gina B.
    Holmes, Matthew
    Melcher, Alan A.
    Lawson, Michelle A.
    Cook, Gordon
    Errington-Mais, Fiona
    CLINICAL CANCER RESEARCH, 2017, 23 (24) : 44 - 44
  • [36] Real life use and outcomes of pomalidomide based anti-myeloma therapies - an analysis from the Austrian Myeloma Registry (AMR)
    Wallner, E.
    Weger, R.
    Agis, H.
    Hartmann, B.
    Sormann, S.
    Krauth, M.
    Willenbacher, E.
    Strassl, I.
    Bauer, F.
    Willenbacher, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 113 - 113
  • [37] "In Vivo Vaccination" Effect in Clinical Responders to Anti-Myeloma Monoclonal Antibody Isatuximab
    Luetkens, Tim
    Yousef, Sara
    Shorter, Christa
    Tantravahi, Srinivas K.
    Steinbach, Mary Nicole
    Weidner, Janet
    Sborov, Douglas W.
    Atanackovic, Djordje
    BLOOD, 2017, 130
  • [38] Multiple myeloma will become a common cancer in the era of modern therapy
    Rosenberg, Philip S.
    Best, Ana
    Anderson, William F.
    Landgren, Ola
    CANCER RESEARCH, 2016, 76
  • [39] The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era
    Salgado, Lucas Resende
    Wang, Shutao
    Adler, Ava
    Chang, Sanders
    Ru, Meng
    Moshier, Erin
    Dharmarajan, Kavita
    Cho, Hearn Jay
    Bakst, Richard
    ADVANCES IN RADIATION ONCOLOGY, 2019, 4 (01) : 112 - 117
  • [40] Anti-myeloma effects induced by myeloma idiotype pulsed dendritic cells in vitro.
    Zhang, M
    Yin, XR
    Luo, YY
    Lin, X
    He, PC
    Wang, MC
    Li, J
    Liu, YL
    Guo, GL
    Cai, RB
    Qiu, L
    BLOOD, 2005, 106 (11) : 366B - 366B
12345